Delayed return of ejaculatory function in adolescent males treated with RPLND and adjuvant therapy for paratesticular rhabdomyosarcoma

Due to the rarity of the disease, adverse events related to ejaculatory function following the management of paratesticular rhabdomyosarcoma (ptRMS) with multi-modal therapy in adolescents are rarely discussed. Two patients, age 14 and 15 at time of diagnosis were treated with multi-modal therapy with nerve-sparing retroperitoneal lymph node dissection (NS-RPLND), chemotherapy, and radiotherapy. Each developed ejaculatory dysfunction during the treatment period, which resolved 1 year after completion of all therapies. We sought to assess the role of each component of multi-modal therapy on the observed side effect and the potential for delayed recovery of function after cessation of all therapies.

Urology. 2018 Oct 23 [Epub ahead of print]

James Rague, Briony K Varda, Andrew A Wagner, Richard S Lee

Boston Medical Center, Department of Urology, Boston, MA., Boston Children's Hospital, Department of Urology, Boston, MA., Beth Israel Deaconess Medical Center, Department of Urology, Boston, MA; Harvard Medical School, Department of Surgery, Boston, MA., Boston Children's Hospital, Department of Urology, Boston, MA; Harvard Medical School, Department of Surgery, Boston, MA. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe